Kimberly-Clark Co. (NYSE:KMB) Shares Bought by Ieq Capital LLC

Ieq Capital LLC lifted its position in shares of Kimberly-Clark Co. (NYSE:KMB) by 23.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 19,212 shares of the company’s stock after acquiring an additional 3,669 shares during the quarter. Ieq Capital LLC’s holdings in Kimberly-Clark were worth $2,655,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Rise Advisors LLC raised its stake in shares of Kimberly-Clark by 926.3% during the 1st quarter. Rise Advisors LLC now owns 195 shares of the company’s stock worth $25,000 after buying an additional 176 shares in the last quarter. Crewe Advisors LLC purchased a new position in Kimberly-Clark in the first quarter worth $27,000. New Millennium Group LLC acquired a new stake in Kimberly-Clark in the second quarter valued at $28,000. Strategic Financial Concepts LLC purchased a new stake in shares of Kimberly-Clark during the 2nd quarter worth $32,000. Finally, Fortitude Family Office LLC grew its stake in shares of Kimberly-Clark by 333.3% during the 2nd quarter. Fortitude Family Office LLC now owns 325 shares of the company’s stock worth $45,000 after purchasing an additional 250 shares during the period. Institutional investors and hedge funds own 76.29% of the company’s stock.

Kimberly-Clark Price Performance

Shares of NYSE:KMB opened at $140.75 on Friday. The company has a market cap of $47.39 billion, a P/E ratio of 25.87, a P/E/G ratio of 3.04 and a beta of 0.39. The business has a fifty day simple moving average of $142.29 and a 200-day simple moving average of $136.10. Kimberly-Clark Co. has a 52 week low of $116.32 and a 52 week high of $149.30. The company has a quick ratio of 0.58, a current ratio of 0.85 and a debt-to-equity ratio of 5.59.

Kimberly-Clark (NYSE:KMB) last posted its quarterly earnings data on Tuesday, July 23rd. The company reported $1.96 EPS for the quarter, beating analysts’ consensus estimates of $1.71 by $0.25. Kimberly-Clark had a net margin of 11.28% and a return on equity of 223.55%. The company had revenue of $5.03 billion during the quarter, compared to the consensus estimate of $5.10 billion. During the same quarter in the prior year, the company posted $1.65 EPS. The company’s quarterly revenue was down 2.0% compared to the same quarter last year. Equities research analysts forecast that Kimberly-Clark Co. will post 7.25 EPS for the current year.

Kimberly-Clark Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 2nd. Shareholders of record on Friday, September 6th will be issued a $1.22 dividend. The ex-dividend date is Friday, September 6th. This represents a $4.88 dividend on an annualized basis and a dividend yield of 3.47%. Kimberly-Clark’s dividend payout ratio (DPR) is presently 89.71%.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on KMB. Bank of America raised shares of Kimberly-Clark from an “underperform” rating to a “buy” rating and boosted their price objective for the stock from $115.00 to $160.00 in a report on Thursday, June 13th. Barclays lowered their price target on Kimberly-Clark from $136.00 to $135.00 and set an “equal weight” rating on the stock in a report on Friday, July 19th. Piper Sandler lifted their price objective on Kimberly-Clark from $167.00 to $174.00 and gave the stock an “overweight” rating in a report on Thursday, July 11th. Royal Bank of Canada reissued an “outperform” rating and issued a $165.00 target price on shares of Kimberly-Clark in a report on Wednesday, July 24th. Finally, Deutsche Bank Aktiengesellschaft lifted their price target on Kimberly-Clark from $139.00 to $142.00 and gave the stock a “hold” rating in a research note on Wednesday, July 24th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $145.67.

Insider Activity

In related news, insider Gonzalo Uribe sold 1,780 shares of Kimberly-Clark stock in a transaction on Monday, July 29th. The stock was sold at an average price of $140.84, for a total value of $250,695.20. Following the transaction, the insider now owns 7,377 shares in the company, valued at $1,038,976.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider Gonzalo Uribe sold 1,780 shares of the firm’s stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $140.84, for a total value of $250,695.20. Following the transaction, the insider now directly owns 7,377 shares in the company, valued at approximately $1,038,976.68. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Jeffrey P. Melucci sold 37,699 shares of the business’s stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $141.42, for a total value of $5,331,392.58. Following the sale, the insider now owns 19,935 shares of the company’s stock, valued at approximately $2,819,207.70. The disclosure for this sale can be found here. Corporate insiders own 0.62% of the company’s stock.

About Kimberly-Clark

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products in the United States. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The company’s Personal Care segment offers disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, reusable underwear, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Thinx, Poise, Depend, Plenitud, Softex, and other brand names.